Abstract 1498P
Background
Acute myeloid leukemia (AML) is a fatal cancer in patients over 65 years old, with a five-year relative survival rate of 10.8%. There is no literature regarding specific determinants of palliative care (PC) utilization in this population. We studied trends and determinants in PC utilization among hospitalized patients using the National Inpatient Sample (NIS).
Methods
This is a retrospective study using NIS data from 2016 to 2020. We included patients aged 65 years or older who were admitted with AML. We identified patients who had an encounter with PC during their hospitalization. The cohort was divided between patients with an encounter with PC and those without. Baseline characteristics were identified and compared between the two groups. Total charges (TC) during hospitalization were measured as an outcome, and then multivariate logistic regression analysis was performed to adjust for confounders.
Results
There were 44,375 patients over 65 years old admitted with AML. Of those, 22% had an encounter with PC. Baseline characteristics and differences between those in which PC was consulted and those in which they were not consulted are depicted in the table. Significant differences were observed in patients who had an encounter with PC, such as higher utilization in the White race (78% vs. 75%). They had higher rates of Heart Failure (HF) (23% vs 17%, p<0.001), acute kidney injury (AKI) (44% vs. 30%, p<0.001), and chronic kidney disease (CKD) (15% vs 12%, p 0.0018) than patients who did not have an encounter with PC. Type of insurance and hospital bed size were not significantly associated with PC utilization. Significantly, PC was consulted less in hospitals in the south region. While adjusting for other confounders, in the multivariate regression analysis, encounters with PC were associated with a decrease in TC during hospitalization of $ 49,047 (p<0.001).
Conclusions
Overall, PC utilization was low. It was reduced in hospitals located in the south region of the USA. It was higher in patients of the White Race and in patients with HF, AKI, and CKD and was associated with decreased cost burden. Our results highlight the need for early palliative care involvement in patients with AML in hospital settings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1502P - Sexual dysfunction and quality of life in rectal cancer
Presenter: Fatih Kus
Session: Poster session 10
1503P - Spiritual needs in cancer patients: A cross-sectional study
Presenter: Diego Toloi
Session: Poster session 10
1546P - Use of ESMO-MCBS Scorecards in supporting funding decisions in private insurance
Presenter: Samantha Field
Session: Poster session 10
1547P - Time from approval to reimbursement of new cancer and non-cancer drugs: A comparative analysis between the US, England, Germany, and Switzerland (2011-2022)
Presenter: Camille Glaus
Session: Poster session 10
1548P - Real-world impact of the platinum chemotherapy shortage on advanced cancer patients
Presenter: Jacob Reibel
Session: Poster session 10
1549P - Accelerating access to innovative oncology drugs: Insights from France's early access reform
Presenter: Tess Martin
Session: Poster session 10
1550P - Addressing uncertainties of clinical value and improving access for newly authorised indications through DRUG-Access Protocol (DAP)-like platforms: Joint collection and evaluation of real-world evidence
Presenter: Sahar van Waalwijk van Doorn-Khosrovani
Session: Poster session 10
1551P - Breakthrough therapy cancer drugs and indications with FDA approval: Development time, innovation, trials, clinical benefit, epidemiology, and price
Presenter: Christoph Michaeli
Session: Poster session 10
1552P - Regulatory approval of novel immunotherapy for lymphoid neoplasm in the US, EU, and Japan
Presenter: Kensuke Matsuda
Session: Poster session 10
1553P - Access to EMA approved drugs in Europe, disparities across a border
Presenter: Orla Fitzpatrick
Session: Poster session 10